Article
CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
International journal of oncology - 1 Apr 2015
Ishikura Nobuyuki, Kawata Hiromitsu, Nishimoto Ayako, Nakamura Ryo, Tsunenari Toshiaki, Watanabe Miho, Tachibana Kazutaka, Shiraishi Takuya, Yoshino Hitoshi, Honma Akie, Emura Takashi, Ohta Masateru, Nakagawa Toshito, Houjo Takao, Corey Eva, Vessella Robert L, Aoki Yuko, Sato Haruhiko
Abstract excerpt
Resistance of prostate cancer to castration is currently an unavoidable problem. The major mechanisms underlying such resistance are androgen receptor (AR) overexpression, androgen-independent activation of AR, and AR mutation. To address this problem, we developed an AR pure antagonist, CH5137291, with AR nuclear translocation-inhibiting activity, and compared its activity and characteristics with that of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.